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Sir,
Olsen et al (2003) claim in their article that organised
mammography screening can operate without overdiagnosis of
breast cancer.
This paper contains no statistical analysis and does not report
the number of detected cancers, so the readers can do the proper
statistical analysis themselves. In particular, it does not report the
incidence increase in per cent, and the readers are left to look at
some figures.
When I look at Figure 2, I read that the cumulative risk in
Copenhagen increases from about 5.25% (1989–91) to 6.25%
(1993–95). This gives 19% increase. Comparing the 5.75%
cumulative risk on Fyn in 1992–93 to 6.75% cumulative risk in
1996–97 shows a 17% increase.
There was some opportunistic screening before organised
screening started in Denmark (Olsen et al, 2003), so there is
reason to attribute some of the incidence increase before 1993 to
mammography. If cumulative risk in the second screening round is
compared to the cumulative risk in 1987–89 (Copenhagen) or
1988–89 (Fyn), I get at least 30 and 50% incidence increases,
respectively.
The authors should also have studied incidence in the age
group 70–74 years after some years with screening in the age
group 50–69 years (Spix et al, 2003). If mammography screening
brings the time of diagnosis forward, incidence in the age group
70–74 years should decline. The difference between incidence
increase in the age group 50–69 years and decline in the age group
70–74 years is the correct definition of overdiagnosis (Spix et al,
2003).
The authors do not report ductal carcinoma in situ (DCIS). On
including DCIS (as Olsen and Gtzsche (2001) did), one would
assume that overdiagnosis today must be a much larger problem
than reported by Olsen and Gtzsche in the screening trials 20
years ago. In contrast, Etzioni et al (2002) recently reported only
30% overdiagnosis when screening with prostate-specific antigen
for prostate cancer.
I think that this paper actually shows that overdiagnosis is a
serious problem when screening with mammography.
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